Tag Archives: metabolic dysfunction-associated steatotic liver disease (MASLD)

Hypertriglyceridaemia: apoC-III inhibition comes of age Professor Maciej Banach (Medical University of Łódź, Poland) Professor Maciej Banach (Medical University of Łódź, Poland) opened with Olezarsen, an antisense oligonucleotide targeting APOC3 messenger RNA that accelerates clearance of triglyceride-rich remnants. In ESSENCE-TIMI 73b (phase 3, n=1,349), it lowered triglycerides by around 60% at six months in moderate hypertriglyceridaemia, with most patients reaching a level below 1.7 mmol/L.1 In the separate CORE-TIMI 72a and CORE2-TIMI 72b trials in severe hypertriglyceridaemia, adjudicated acute pancreatitis was significantly les